Category Archives: MS Treatment

MS Dhoni today paid tribute to Yuvraj Singh as the Indian prepares to return to Test cricket after winning his battle with cancer. The 30-year-old has not played Test cricket for a year after treatment for a rare form of lung cancer. He made a successful international return in the World T20 before scoring a double century in the Duleep Trophy followed by five wickets and a 50 for India A against England. Dhoni said today: He looks in good shape. It takes a lot of fitness to score a double hundred. Im just hoping he does not have to field for two days. There is no need for the car which is capable of a long haul to be driven the full distance. Dhoni said Yuvrajs recovery is an indication of his character. Hes aggressive, said the skipper. Hes someone who really wants to perform at the top level. The best thing for us is he bats at five or six and is a left-arm spinnner. Its a very important role for us because we dont have a genuine all-rounder and play with four bowlers. His contribution will be very important. He can be quite intimidating the way he … Continue reading →

The original whistleblower in the North Wales care home scandal has told Sky News abuse victims are being failed again. Alison Taylor campaigned for years on behalf of the victims after taking the brave decision to speak out. In 1986 she was sacked as head of a North Wales care home but her determination to expose abuse led to police investigations, criminal prosecutions and eventually the Waterhouse Inquiry. Ms Taylor is now dismayed at the media storm surrounding the botched Newsnight broadcast and the implications it has for victims of child abuse. She told Sky News: "I think it has thrown us right back to the pre-North Wales investigations." "It was hard enough then - it was a real uphill struggle to get the police to investigate anything." Ms Taylor also believes that Steve Messham, the man who originally spoke to Newsnight about his alleged abusers and has now acknowledged that he was mistaken, is now being unfairly treated. She said: "Steve, who genuinely was a victim, is now being perceived in some quarters as a man who has made false allegations. "There are a lot of people who clearly have a vested interest in playing down the abuse allegations." … Continue reading →

Justice Minister Judith Collins has marked the first hearings at the Alcohol and Other Drug Treatment (AODT) Court pilot sitting in Auckland and Waitakere District Courts today. Ms Collins says it is extremely pleasing the pilot Court is now up and running, helping to reduce re-offending by supporting offenders who make a serious commitment to change. "This AODT Court is a first for New Zealand. I am delighted we now have a Court that can deliver a new holistic approach to reducing re-offending. "The AODT Court gives offenders an opportunity to confront the drug and alcohol dependency that has fuelled their offending, giving them the tools and support they need to free themselves from a life of addiction. "Re-offending has fallen by almost 7 per cent over the past year. If we are to continue delivering results, we need to explore innovative new ways of working. The AODT Court is a perfect example of this in action," Ms Collins says. When the pilot Court has been running for a significant length of time, it will be evaluated for success in treatment outcomes, reduction in reoffending, and cost effectiveness. "Studies of the effect of AODT on recidivism rates in the United … Continue reading →

In autumn of 2009, Ali Salama was training for the ING New York City marathon and felt some numbness in her legs. Originally, she attributed the problem to shin splints and took a break. But the pain wasnt going away, so she decided to see a neurologist. At the age of 35, Salama was diagnosed with multiple sclerosis, a disease which has no cure and affects 2.5 million people around the world. The autoimmune disorder attacks the bodys nervous system and can lead to numbness, paralysis and loss of vision. - Ali Salama, MS patient of learning about new oral pill Salama said she was shocked. You read about it. You obviously go on websites, (and) you see that people are in wheelchairs and how mobility becomes more difficult, Salama said. Theres vision issues, so all those things run through your mind. Salama said she wondered about the treatment and became fearful when she learned many treatment options included something she always hated shots. Dr. Aaron Miller, medical director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mt. Sinai School of Medicine in NYC and Salamas doctor, said he was primarily prescribing injectable medications for his patients. These, … Continue reading →

HOUSTON, Nov. 7, 2012 /PRNewswire/ --Frederick Churbuckis the first person in the United States to have completed treatment utilizing the AcceleDent device designed to accelerate orthodontic tooth movement. He was able to have his braces removed after just over 9 months of treatment, which is significantly less time than the 18 months predicted. The treatment was administered by Dr. Robert Rudman, DDS, MS, of Denver, Colorado. Dr. Rudman graduated Magna Cum Laude from Marquette University School of Dentistry and has been described as among the top orthodontists in the world. Mr. Churbuck, Market General Manager at LivingSocial in Denver, enthuses, "My teeth are beautiful and in 9 months. It feels too good to be true. I am in a place so far beyond thrilled that I never even knew existed." He continues, "I am seriously an evangelist for AcceleDent. As they say, I'm on fire with the brand and most importantly my results." Dr. Rudman, commented, "Orthodontic technology is rapidly evolving in many areas, but innovation geared at significantly shortening treatment times have not proven effective until now. AcceleDent offers the first non-invasive product to successfully and safely address our patients' desire to dramatically shorten treatment, while still maintaining the … Continue reading →

ST. LOUIS A weekly clinic for people with multiple sclerosis has reopened at Barnes-Jewish Hospital after low funds forced its closure in July. The Gateway Area Chapter of the National Multiple Sclerosis Society donated $50,000 to the John L. Trotter MS Center, which serves patients with Medicaid or no insurance. They are very committed to making sure MS patients in the region have access to an MS specialist, said Dr. Robert Naismith, a neurologist and director of the clinic. About 400,000 people in the U.S. have multiple sclerosis, a degenerative disease of the central nervous system that can cause symptoms ranging from numbness and weakness in the limbs to fatigue and vision impairment. The course of the disease and severity of symptoms varies in each person with MS. Most people with MS take disease-modifying drugs with a goal of slowing its progression. The clinic will serve 150 to 200 patients when it is open a half day each week. Each patient is expected to visit the clinic at least once a year. It is named for Dr. John Trotter, a leading MS researcher and clinician at Washington University who died in 2001. Each new patient will spend an hour with … Continue reading →

Public release date: 31-Oct-2012 [ | E-mail | Share ] Contact: Genevieve Maul Genevieve.maul@admin.cam.ac.uk 44-012-237-65542 University of Cambridge A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published today in the journal The Lancet. The new studies, sponsored by Genzyme (a Sanofi company) and Bayer Schering Pharma, showed that alemtuzumab significantly reduces the number of attacks (or relapses) experienced by people with MS compared to interferon beta-1a (known commercially as Rebif). This was seen both in patients who had not previously received any treatment (drug-nave) and those who have continued to show disease activity whilst taking an existing treatment for MS. In the CARE MSII trial, confined to patients who had recently relapsed on a licenced therapy, new episodes were reduced by 49 per cent more than that achieved by the current standard treatment for MS, interferon beta-1a. Over a two year period, 65 per cent of patients on alemtuzumab compared … Continue reading →

A MOTHER who was having a massage when her toddler was crushed to death as the table was lowered says the clinic welcomed children in its rooms. "I felt safe there and I felt my children were safe there," Justine Schulz told the Adelaide inquest into the death of her daughter Sophie. Ms Schulz was giving evidence on Monday to Adelaide Coroners Court into the death of Sophie, who was 18 months-old when she suffered major head injuries and died at the Fravira Clinic in St Morris on June 17, 2009. Counsel assisting the coroner, Amy Cacas, said children were welcome at the clinic as patients and when they accompanied parents or guardians. On June 17, Sophie and her four-year-old brother were in the treatment room with their mother, playing with toys supplied by the clinic. The therapist, Mira Maric, pressed a pedal to lower the massage table for the last stage of the treatment. "They heard a grunting sound emanating from below the table and found Sophie trapped in the workings of the machine," Ms Cacas said. Ms Maric tried to raise the table, but it would not move, and others ran into the room but were unable to … Continue reading →

CLAREMONT - Ms. Magazine celebrated four decades of feminist journalism with a panel discussion at Scripps College Thursday night in which an editor said the magazine is taking a strong stance against anti-abortion extremists. "These are not lone wolves who are acting out of a deep moral sense of their concern over unborn children," said Ms. Magazine executive editor Kathy Spillar. "This is a network of domestic terrorists that functions like every other network of terrorists. They recruit, they arm, they plan their targets and they commit the violence. All we've ever had until now is the prosecution of the one person who actually plants the bomb or pulls the trigger. "And until you dismantle the network that's behind the terrorism you're never going to see an end to it. We face a very real terrorist threat in this country that is using abortion. They're also very anti-government of any kind. They're usually also very racist and this is a network that will continue to commit violence and perpetuate this mythology that abortion is controversial. And this is hurting us terribly." Legal abortion, Spillar said, has been settled and is not a "real" debate. "Forty percent plus of women will … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012 online issue of The Lancet. In CARE-MS I and CARE-MS II, LEMTRADA was significantly more effective at reducing annualized relapse rates than the active comparator Rebif (high dose subcutaneous interferon beta-1a), and more patients on LEMTRADA were relapse-free at two years. In addition, in CARE-MS II, accumulation of disability was significantly slowed in patients given LEMTRADA vs. Rebif. Further, patients treated with LEMTRADA were significantly more likely to experience improvement in disability scores than those treated with Rebif, suggesting a reversal of disability in some patients. There is a tremendous unmet need for treatments that address the progression of disability that people living with multiple sclerosis can experience, said Genzyme President and CEO, David Meeker, MD. Genzyme set a new standard by comparing LEMTRADA exclusively to an approved treatment in all of our studies. Publication of these findings by The Lancet highlights the importance of these results to the MS community. CARE-MS I and CARE-MS II Efficacy Results CARE-MS … Continue reading →